Skip to main content
SpringerLink
Log in

Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies

  • Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

The purpose of this study was to assess the risk factors for, and the clinical relevance of, faecal carriage by extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) in neutropenic cancer patients (NCP). An observational prospective multicentre cohort study was conducted over 2 years at two teaching hospitals. Patients with acute leukaemia or undergoing stem cell transplantation were included during neutropenia episodes. Rectal swabs were obtained at hospital admission and weekly thereafter until discharge or death. ESBL-EC colonized episodes were compared with non-colonized episodes. ESBL-EC strains were studied by PCR and isoelectric focusing, and molecular typing was performed by pulsed field gel electrophoresis (PFGE). Among 217 episodes of neutropenia, the prevalence of ESBL-EC faecal carriage was 29% (14% at hospital admission). Multivariate analysis identified previous antibiotics as the only independent risk factor for ESBL-EC faecal colonization (OR 5.38; 95% CI 2.79–10.39). Analysis of ESBL-EC isolates revealed a polyclonal distribution with CTX-M predominance (81.3%). E. coli bacteraemia was mainly caused by non-ESBL producing strains and its rate was similar in both groups (13% vs. 11%). We found no association between ESBL-EC carriage and an increased risk of ESBL-EC bacteremia or a negative influence on other clinical outcomes, including length of hospitalisation, early and overall mortality rates. ESBL-EC faecal colonization is frequent in NCP but difficult to identify by epidemiological or clinical features on presentation. Prior antibiotic therapy is the major associated risk factor. In this setting colonization does not appear to have a significant clinical relevance. Thus, routine testing for ESBL-EC faecal carriage does not seem to be beneficial.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Carratalà J, Fernández-Sevilla A, Tubau F et al (1995) Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 20:557–560

    PubMed  Google Scholar 

  2. Carratalà J, Fernandez-Sevilla A, Tubau F et al (1996) Emergence of fluoroquionolne-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prohylaxis. Antimicrob Agents Chemother 40:503–505

    PubMed  Google Scholar 

  3. Yoo JH, Huh DH, Choi JH et al (1997) Molecular epidemiological analysis of quinolone-resistant Escherichia coli causing bacteremia in neutropenic patients with leukemia in Korea. Clin Infect Dis 25:1385–1391

    Article  CAS  PubMed  Google Scholar 

  4. Zinner SH (1999) Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 29:490–494

    Article  CAS  PubMed  Google Scholar 

  5. Ortega M, Marco F, Soriano A et al (2009) Analysis of 4758 Escherichia coli bacteremia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on outcome. J Antimicrob Chemother 63:568–574

    Article  CAS  PubMed  Google Scholar 

  6. Pitout JD, Laupland KB (2008) Extended-spectrum beta-lactamase-producing enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 8:159–166

    Article  CAS  PubMed  Google Scholar 

  7. Rodríguez-Baño J, Alcalá JC, Cisneros JM et al (2008) Community infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Arch Intern Med 168:1897–1902

    Article  PubMed  Google Scholar 

  8. Rodriguez-Baño J, Paterson DL (2006) A change in the epidemiology of infections due to extended-spectrum beta-lactamase-producing organisms. Clin Infect Dis 42:935–937

    Article  PubMed  Google Scholar 

  9. Trecarichi EM, Tumbarello M, Spanu T et al (2009) Incidence and clinical impact of extended-spectrum-β-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect 58:299–307

    Article  PubMed  Google Scholar 

  10. Calatayud L, Arnan M, Liñares J et al (2008) Prospective study of fecal colonization by extended-spectrum β-lactamase-producing Escherichia coli in neutropenic patients with cancer. Antimicrob Agents Chemother 52:4187–4190

    Article  CAS  PubMed  Google Scholar 

  11. Peña C, Pujol M, Ardanuy C et al (1998) Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 42:53–58

    PubMed  Google Scholar 

  12. Clinical and Laboratory Standards Institute (2007) Performance standards for antimicrobial susceptibility testing: fifteenth informational supplement M100-S15. CLSI, Wayne, PA, USA

    Google Scholar 

  13. Tenover FC, Arbeit RD, Goering RV et al (1995) Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33:2233–2239

    CAS  PubMed  Google Scholar 

  14. Fang H, Ataker F, Hedin G et al (2008) Molecular epidemiology of extended-spectrum beta-lactamases among Escherichia coli isolates collected in a Swedish hospital and its associated health care facilities from 2001 to 2006. J Clin Microbiol 46:707–712

    Article  CAS  PubMed  Google Scholar 

  15. Hosmer DW, Lemeshow S (2000) Logistic regression: variable selection. In: Hosmer DW, Lemeshow S (eds) Applied logistic regression, 2nd edn. Wiley, New York, pp 92–115

    Google Scholar 

  16. Ben-Ami R, Schwaber MJ, Navon-Venezia S et al (2006) Influx of extended-spectrum β-lactamase-producing enterobacteriaceae into the hospital. Clin Infect Dis 42:925–934

    Article  CAS  PubMed  Google Scholar 

  17. Castillo García FJ, Seral García C, Pardos de la Gandara M et al (2007) Prevalence of fecal carriage of ESBL-producing Enterobacteriaceae in hospitalized and ambulatory patients during two non-outbreak periods. Eur J Clin Microbiol Infect Dis 26:77–78

    Article  PubMed  Google Scholar 

  18. Kader AA, Kumar A (2007) Fecal carriage of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in patients and asymptomatic healthy individuals. Infect Control Hosp Epidemiol 28:1114–1116

    Article  PubMed  Google Scholar 

  19. Rodríguez-Baño J, López-Cerero L, Navarro MD et al (2008) Faecal carriage of extended-spectrum β-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology. J Antimicrob Chemother 62:1142–1149

    Article  PubMed  Google Scholar 

  20. Valverde A, Coque TM, Sánchez-Moreno MP et al (2004) Dramatic increase in prevalence of fecal carriage of extended-spectrum β-lactamase-producing enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol 42:4769–4775

    Article  CAS  PubMed  Google Scholar 

  21. Mirelis B, Navarro F, Miró E et al (2003) Community transmission of extended-spectrum betalactamases. Emerg Infect Dis 9:1024–1025

    PubMed  Google Scholar 

  22. Miró E, Mirelis B, Navarro F et al (2005) Surveillance of extended-spectrum beta-lactamases from clinical samples and faecal carriers in Barcelona, Spain. J Antimicrob Chemother 56:1152–1155

    Article  PubMed  Google Scholar 

  23. Peña C, Gudiol C, Tubau F et al (2006) Risk-factors for acquisition of extended-spectrum β-lactamase producing Escherichia coli among hospitalised patients. Clin Microbiol Infect 12:279–284

    Article  PubMed  Google Scholar 

  24. Ben-Ami R, Rodríguez-Baño J, Arslan H et al (2009) A multinational survey of risk factors for infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 49:682–690

    Article  PubMed  Google Scholar 

  25. Imran H, Im T, Arndt CA et al (2008) Fluoroquinolone prophylaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials. Eur J Clin Microbiol Infect Dis 27:53–63

    Article  CAS  PubMed  Google Scholar 

  26. Rodríguez-Baño J, Navarro MD, Romero L et al (2006) Bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 43:1407–1414

    Article  PubMed  Google Scholar 

  27. Paterson DL, Bonomo RA (2005) Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 18:657–686

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology Department, Hospital Duran i Reynals, l´Hospitalet de Llobregat, Barcelona, Spain

    M. Arnan

  2. Infectious Disease Department, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, University of Barcelona, Feixa Llarga s/n, 08907, Barcelona, Spain

    C. Gudiol, J. Carratalà & F. Gudiol

  3. REIPI (Spanish Network for Research in Infectious Diseases), Instituto de Salud Carlos III, Madrid, Spain

    C. Gudiol, J. Carratalà & F. Gudiol

  4. Microbiology Department, Hospital Universitari de Bellvitge, l´Hospitalet de Llobregat, Barcelona, Spain

    L. Calatayud, J. Liñares & M. Á. Dominguez

  5. Ciber de Enfermedades Respiratorias, ISCIII, Madrid, Spain

    L. Calatayud & J. Liñares

  6. Haematology Department, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain

    M. Batlle & J. M. Ribera

Authors
  1. M. Arnan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Gudiol
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Calatayud
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Liñares
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Á. Dominguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Batlle
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. M. Ribera
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. Carratalà
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. F. Gudiol
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Gudiol.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arnan, M., Gudiol, C., Calatayud, L. et al. Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. Eur J Clin Microbiol Infect Dis 30, 355–360 (2011). https://doi.org/10.1007/s10096-010-1093-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-010-1093-x

Keywords

Search

Navigation